Pruritus Therapeutics Market Size
Pruritus Therapeutics Market is reached US$ 9.09 billion in 2025 and is expected to reach US$ 12.50 billion by 2033, growing with a CAGR of 3.7% during the forecast period 2026-2033.
Pruritus, or itch, is commonly associated with primary skin disorders such as atopic dermatitis, urticaria, psoriasis, Masto cytosis, and dermatitis herpetiformis, among others. A typical itching generally forms the diagnosis of a major dermatologic disorder. Several skin diseases related to pruritus, such as renal pruritus, hematologic pruritus, cholestatic pruritus, idiopathic generalized pruritus, pruritus related to malignancy and endocrine pruritus. Increased ions such as calcium, phosphate, and magnesium are found in pruritic patients' skin. Severe pruritus leads to scratching that causes secondary skin problems such as eczematisation, dryness, infection, excoriation, Contact allergy, and lichenification.
As per DataM Intelligence, Pruritus Therapeutics Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Pruritus Therapeutics Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.
Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Pruritus Therapeutics Market in the United States and Canada produces the utmost share. Whereas the European Pruritus Therapeutics Market is projected to continue its presence globally during the period of 2024-2031.
Pruritus Therapeutics Market Scope
| Metrics | Details |
| Market CAGR | 3.7% |
| Segments Covered | By Disease Type, By Route of Administration, By Drug Class, By Distribution Channel, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For More Insights - Request Free Sample
Pruritus Therapeutics Market Dynamics
The global pruritus therapeutics market is growing due to several factors, such as the increasing incidence of dermatological disorders influencing the occurrence of pruritus and the growing demand for proper diagnostics and therapeutics to treat such medical conditions.
The development of new therapeutics for pruritus is forcing global market growth.
The development of new targeted therapies for different pruritus is driving the growth of the global pruritus therapeutics market. For instance, the development of Duplimab, which is a monoclonal antibody that specifically targets interleukin-4 receptors that are involved in the progression of the inflammatory response with these other novel therapeutics, for example, Crisaborole 2% ointment and others are in the pipeline of major key market players for topical medication including the Janus kinase inhibitors. Furthermore, the approval of these newly developed therapeutics by different regulatory bodies propels the market towards growth. For instance, in June 2022, Dupixent (Duplimab), developed by Sanofi, is the first biologics medicine validated by the United States Food and Drug Administration to treat moderate to severe dermatitis in children aged 6 months to 5 years. These market events and the development of new therapeutics are fueling the market growth globally.
The lack of awareness and incidences of drug side effects will become a hurdle in the pruritus therapeutics market growth.
However, the lack of awareness towards therapeutics for pruritus and the associated side effects associated with pruritus therapeutics hinder the market's growth.
Industry analysis
The pruritus therapeutics market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, research and developments, epidemiology, regulatory analysis, pricing analysis and pipeline analysis, Etc.
Pruritus Therapeutics Market Companies and Competitive Landscape
The pruritus therapeutics market is competitive, with few major players competing to gain market share. Some major players in the global pruritus therapeutics market include Allergan Inc., Amgen Inc., Astellas Pharma Inc., CARA Therapeutics, Novartis AG, Teva Pharmaceutical Industries Ltd, Pfizer, Sanofi, GlaxoSmithKline, Merck, among others. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations contributing to the global Pruritus Therapeutics market's growth.
Leo Pharma
Overview
Leo Pharma is a leading company in the dermatology market, founded in 1908 and headquartered in Denmark. It is primarily focused on research and development to advance the science of dermatology.
Product Portfolio
Leo Pharma’s dermatological product portfolio has Adtralza, Dovobet, Dovonex, Enstilar, Finacea, Kyntheum, Protopic, Skinoren, Fucidin, and Fucibet.
Recent Developments
- March 2026 – GlaxoSmithKline plc secures FDA approval for novel pruritus drug in liver disease
The U.S. FDA approved GSK’s drug (Lynavoy/linerixibat) for cholestatic pruritus in primary biliary cholangitis (PBC), marking a major advancement as existing therapies did not directly target itching symptoms. - March 2026 – Licensing deal strengthens commercialization of pruritus therapy pipeline
GSK entered a USD 690 million licensing agreement with Alfasigma for linerixibat, enabling global commercialization and accelerating access to advanced pruritus treatments. - February 2026 – Increasing investment in biologics and targeted itch therapies
Companies such as Amgen Inc., Novartis AG, and Pfizer Inc. are expanding pipelines focused on biologics, immunomodulators, and cytokine-targeting therapies to address chronic itch conditions. - February 2026 – Growing focus on non-steroidal and safer long-term treatments
There is a strong shift away from corticosteroids toward non-steroidal therapies (e.g., JAK inhibitors, biologics, calcineurin inhibitors) to minimize long-term side effects and improve patient safety.
The global pruritus therapeutics market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) page.
